Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion type Assertion NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_head.
- NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion description "[Of the informative human hepatocellular carcinoma samples 47.06% (8 of 17) demonstrated a gain of imprinting of IGF2, and 21.74% (5 of 23) of the informative HCC samples demonstrated a loss of imprinting of H19.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_provenance.
- NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion evidence source_evidence_literature NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_provenance.
- NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion SIO_000772 18358696 NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_provenance.
- NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion wasDerivedFrom lhgdn-20090331 NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_provenance.
- NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_assertion wasGeneratedBy ECO_0000203 NP116025.RA7VAG4WDwxc71v5Mc9Fb1Dn3s85v6ad4eEYulE8Cp3G4130_provenance.